HC Wainwright Has Negative Outlook of NAMS FY2025 Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Stock analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in a report released on Wednesday, November 5th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($1.68) per share for the year, down from their previous estimate of ($1.42). HC Wainwright currently has a “Buy” rating and a $52.00 target price on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2025 earnings at ($0.55) EPS and FY2026 earnings at ($1.33) EPS.

A number of other research firms have also recently commented on NAMS. The Goldman Sachs Group began coverage on shares of NewAmsterdam Pharma in a research note on Thursday, July 17th. They set a “neutral” rating and a $27.00 price target for the company. Royal Bank Of Canada boosted their target price on NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an “outperform” rating in a research report on Thursday. Wells Fargo & Company initiated coverage on NewAmsterdam Pharma in a report on Monday, August 25th. They issued an “overweight” rating and a $45.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. Finally, Needham & Company LLC upped their price objective on NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $44.30.

NewAmsterdam Pharma Trading Down 0.8%

Shares of NAMS opened at $36.76 on Monday. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $41.47. The company has a market cap of $4.14 billion, a P/E ratio of -17.93 and a beta of 0.05. The company’s fifty day simple moving average is $31.43 and its 200-day simple moving average is $24.51.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The company had revenue of $0.35 million during the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.

Institutional Trading of NewAmsterdam Pharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Mather Group LLC. bought a new position in NewAmsterdam Pharma during the 3rd quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at about $30,000. Quarry LP purchased a new stake in shares of NewAmsterdam Pharma in the 1st quarter worth approximately $25,000. Wolverine Asset Management LLC purchased a new stake in shares of NewAmsterdam Pharma in the 3rd quarter worth approximately $69,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of NewAmsterdam Pharma by 18.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock valued at $79,000 after purchasing an additional 662 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

Insider Activity at NewAmsterdam Pharma

In other news, Director James N. Topper acquired 1,260 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were bought at an average price of $24.99 per share, with a total value of $31,487.40. Following the completion of the purchase, the director directly owned 3,027,864 shares in the company, valued at $75,666,321.36. This trade represents a 0.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the firm’s stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $24.29, for a total value of $1,214,500.00. Following the transaction, the insider owned 119,302 shares in the company, valued at $2,897,845.58. The trade was a 29.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 226,342 shares of company stock worth $5,748,019. Company insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.